Despite large unmet medical needs in the field for several decades, CNS drug discovery
and development has been largely unsuccessful. Biomarkers, particularly those utilizing …

Four novel phosphodiesterase 10A (PDE10A) PET tracers have been synthesized, characterized
in preclinical studies, and compared with the previously reported 11 C-MP-10. Methods…

Visualization of neurotransmission components in living small animals using positron
emission tomography (PET) has the potential of contributing to the preclinical development of …

… Takafumi Minamimoto and Takeaki Saijo designed experiments and discussed the data. …
, Hajime Fukuda, Tatsuo Nakajima, and Takeaki Saijo are full-time employees of Mitsubishi …

Extracellular vesicles (EVs) are lipid bilayer particles that are released by various cells and
provide a real-time snapshot of the state of these cells in tissue in a noninvasive manner. EVs …

Phosphodiesterase (PDE) 10A is an attractive therapeutic target for schizophrenia. Here,
we investigated the antipsychotic-like effects of a novel PDE10A inhibitor, 1-({2-(7-fluoro-3-…

A novel investigational antidepressant with high affinity for the serotonin transporter and the
serotonin 1A (5-HT 1A ) receptor, called Wf-516 (structural formula: (2S)-1-[4-(3,4-…

Background: Central substance P receptors, termed NK-1 receptors, have been considered
as therapeutic targets in the development of drugs against diverse conditions, including …

We have developed 8‐amino‐3‐(2S,5R‐dimethyl‐1‐piperidyl)‐[1,2,4]triazolo[4,3‐a]pyrazine‐5‐[
11 C]carbonitrile ([ 11 C]MTP38) as a positron emission tomography (PET) tracer for …

Purpose Phosphodiesterase (PDE) 7 is a potential therapeutic target for neurological and
inflammatory diseases, although in-vivo visualization of PDE7 has not been successful. In this …